These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 22622251

  • 1. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R, Minichino A, Pignatelli M, Delle Chiaie R, Biondi M, Nicoletti F.
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [Abstract] [Full Text] [Related]

  • 2. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
    Chaki S.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):59-66. PubMed ID: 20371240
    [Abstract] [Full Text] [Related]

  • 3. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
    Chavez-Noriega LE, Schaffhauser H, Campbell UC.
    Curr Drug Targets CNS Neurol Disord; 2002 Jun 10; 1(3):261-81. PubMed ID: 12769619
    [Abstract] [Full Text] [Related]

  • 4. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S, Hikichi H.
    Curr Pharm Des; 2011 Jun 10; 17(2):94-102. PubMed ID: 21355835
    [Abstract] [Full Text] [Related]

  • 5. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC.
    Int Rev Neurobiol; 2007 Jun 10; 78():69-108. PubMed ID: 17349858
    [Abstract] [Full Text] [Related]

  • 6. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct 10; 27(7):1113-23. PubMed ID: 14642971
    [Abstract] [Full Text] [Related]

  • 7. Glutamate signaling in the pathophysiology and therapy of schizophrenia.
    Lin CH, Lane HY, Tsai GE.
    Pharmacol Biochem Behav; 2012 Feb 10; 100(4):665-77. PubMed ID: 21463651
    [Abstract] [Full Text] [Related]

  • 8. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M, Nagel J, Gravius A, Schäfer D, Danysz W.
    Amino Acids; 2007 Feb 10; 32(2):173-8. PubMed ID: 16699816
    [Abstract] [Full Text] [Related]

  • 9. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
    Fell MJ, McKinzie DL, Monn JA, Svensson KA.
    Neuropharmacology; 2012 Mar 10; 62(3):1473-83. PubMed ID: 21704048
    [Abstract] [Full Text] [Related]

  • 10. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U.
    Expert Opin Emerg Drugs; 2005 Nov 10; 10(4):827-44. PubMed ID: 16262565
    [Abstract] [Full Text] [Related]

  • 11. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.
    Wang SJ, Yang TT.
    Drug News Perspect; 2005 Nov 10; 18(9):561-6. PubMed ID: 16421629
    [Abstract] [Full Text] [Related]

  • 12. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K, Iyo M.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb 10; 22(1):3-13. PubMed ID: 11917507
    [Abstract] [Full Text] [Related]

  • 13. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.
    Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.
    Curr Top Med Chem; 2013 Feb 10; 13(1):26-54. PubMed ID: 23409764
    [Abstract] [Full Text] [Related]

  • 14. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.
    Mol Pharmacol; 2010 Mar 10; 77(3):317-26. PubMed ID: 19933774
    [Abstract] [Full Text] [Related]

  • 15. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
    Lesage A, Steckler T.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):2-16. PubMed ID: 20371230
    [Abstract] [Full Text] [Related]

  • 16. Metabotropic glutamate receptor 7: at the interface of cognition and emotion.
    O'Connor RM, Finger BC, Flor PJ, Cryan JF.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):123-31. PubMed ID: 20371242
    [Abstract] [Full Text] [Related]

  • 17. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M.
    Pol J Pharmacol; 2003 Aug 10; 55(2):133-54. PubMed ID: 12926541
    [Abstract] [Full Text] [Related]

  • 18. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs.
    Fumagalli F, Frasca A, Racagni G, Riva MA.
    Mol Pharmacol; 2008 May 10; 73(5):1484-90. PubMed ID: 18250147
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA.
    Mol Psychiatry; 2012 Dec 10; 17(12):1206-27. PubMed ID: 22584864
    [Abstract] [Full Text] [Related]

  • 20. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
    Doreulee N, Alania M, Mitaishvili E, Chikovani M, Chkhartishvili B.
    Georgian Med News; 2009 Dec 10; (177):59-65. PubMed ID: 20090156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.